Clemondo Group (CLEM) Q4 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2024 earnings summary
5 Jun, 2025Executive summary
Q4 2024 net sales rose 1% to 70.2 MSEK, with EBITDA at 6.5 MSEK and EBIT at 3.2 MSEK, both down year-over-year due to increased growth investments.
Full-year 2024 sales declined 6% to 262.1 MSEK, with EBITDA at 23.8 MSEK and EBIT at 9.2 MSEK, reflecting weak demand in the Vehicle segment.
Solid financial position with equity ratio at 62.4% and net debt reduced to 22.5 MSEK by year-end.
Growth in Hygiene (+8%) and Industry (+14%) segments offset by a 6% decline in Vehicle sales in Q4.
Positive outlook for 2025, supported by a major hygiene contract worth up to 44 MSEK over four years.
Financial highlights
Q4 2024: Net sales 70.2 MSEK (69.5), EBITDA 6.5 MSEK (7.9), EBIT 3.2 MSEK (4.0), net income 2.5 MSEK (3.0), EPS 0.18 SEK (0.22).
Full-year 2024: Net sales 262.1 MSEK (278.9), EBITDA 23.8 MSEK (31.9), EBIT 9.2 MSEK (16.4), net income 6.2 MSEK (10.0), EPS 0.45 SEK (0.72).
Gross margin Q4: 39.1% (39.7%).
Operating cash flow Q4: 8.4 MSEK (10.9).
No dividend proposed for 2024.
Outlook and guidance
Entering 2025 with improved position, strong equity, and focus on growth.
Major hygiene contract with Västra Götalandsregionen to start May 2025, valued at 11 MSEK annually.
Management expects continued growth in Hygiene and Industry, with stabilization in Vehicle.
Latest events from Clemondo Group
- Q4 2025 saw 11% sales growth, margin pressure from investments, and strong Medical Care gains.CLEM
Q4 202526 Feb 2026 - Q3 2025 saw 13% sales growth and strong segment performance, but lower margins due to investments.CLEM
Q3 202511 Nov 2025 - Net sales rose 9% year-over-year, with strong growth in Medical Care and Industrial segments.CLEM
Q2 202520 Aug 2025 - Q3 2024 saw stable earnings, strong equity, and growth in Hygien and Industri amid a weak market.CLEM
Q3 202413 Jun 2025 - Sales declined but gross margin and financial position improved, with growth in Hygiene and Industry.CLEM
Q2 202413 Jun 2025 - Q1 2025 saw 12% sales growth, margin expansion, and Medical Care emerge as a key growth driver.CLEM
Q1 20256 Jun 2025